Direct oral anticoagulants and cardiovascular market transformation — the decade-long disruption of the anticoagulation pharmaceutical market by direct oral anticoagulants (DOACs — apixaban/Eliquis, rivaroxaban/Xarelto, edoxaban/Savaysa, dabigatran/Pradaxa) largely displacing warfarin for atrial fibrillation stroke prevention, venous thromboembolism treatment, and post-arthroplasty...